SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-19-016480
Filing Date
2019-05-07
Accepted
2019-05-07 16:01:49
Documents
57
Period of Report
2019-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q allo-10q_20190331.htm 10-Q 1767949
2 EX-10.2 allo-ex10_104.htm EX-10 335186
3 EX-31.1 allo-ex311_103.htm EX-31.1 15961
4 EX-31.2 allo-ex312_101.htm EX-31.2 15953
5 EX-32.1 allo-ex321_102.htm EX-32.1 9013
  Complete submission text file 0001564590-19-016480.txt   6667321

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT allo-20190331.xml EX-101.INS 1433904
7 XBRL TAXONOMY EXTENSION SCHEMA allo-20190331.xsd EX-101.SCH 43887
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE allo-20190331_cal.xml EX-101.CAL 45049
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE allo-20190331_def.xml EX-101.DEF 160155
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE allo-20190331_lab.xml EX-101.LAB 366118
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE allo-20190331_pre.xml EX-101.PRE 266924
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38693 | Film No.: 19802990
SIC: 2836 Biological Products, (No Diagnostic Substances)